Brain

Epilepsy Foundation of America to Present Lifetime Accelerator Award to Orrin Devinsky, M.D.

Renowned Neurologist and Epilepsy Advocate Honored for Decades of Innovation in Therapeutics, Research, and Patient Care BOWIE, Md., May 14,…

7 months ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

- VCN-01 Achieves Primary Efficacy and Safety Endpoints for Pancreatic Ductal Adenocarcinoma in VIRAGE Phase 2b Clinical Trial - -…

7 months ago

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001 in Treatment of Psychiatric Disorders

VANCOUVER, British Columbia, May 14, 2025 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB…

7 months ago

FDA and Cingulate Aligned with Filing Requirements for New Drug Application for Lead ADHD Asset CTx-1301

Pre-NDA Minutes from April 2, 2025, Meeting Received NDA Submission Planned this Summer KANSAS CITY, Kan., May 14, 2025 (GLOBE…

7 months ago

Plus Therapeutics’ REYOBIQ™ Shows Clinical Benefit and Safety in the ReSPECT-LM Clinical Trial for Patients with Leptomeningeal Metastases (LM)

Multiple long-term LM survivors in those patients receiving multiple doses of REYOBIQ RNA sequencing data show early tumor apoptosis and…

7 months ago

PreveCeutical Medical Inc. Announces Launch of New Website for BioGene Therapeutics Inc., Expanding Its Digital Presence to Enhance Accessibility and Awareness of Innovative Therapies

Vancouver, British Columbia--(Newsfile Corp. - May 14, 2025) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) ("PreveCeutical"), a…

7 months ago

Creyos Partners with Redox to Eliminate Barriers to Cognitive Health Data in EHRs

Partnership redefines how health systems bring cognitive screening into routine care at scale TORONTO, May 13, 2025 /PRNewswire/ -- Creyos,…

7 months ago

Shineco’s Subsidiary InfiniClone Partners with Total World Marketing for Entry into the Southeast Asian Healthcare Market

BEIJING, May 13, 2025 (GLOBE NEWSWIRE) -- Shineco, Inc. ("Shineco" or the "Company"; NASDAQ: SISI), a provider of innovative diagnostic…

7 months ago

Oragenics, Inc. Announces Approval to Initiate Phase II Concussion Drug Trial in Australia

SARASOTA, Fla., May 13, 2025 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a biotechnology company focused on developing novel…

7 months ago

Bright Minds Biosciences Announces Positive Findings from its DBA/2 Mouse Model Study Evaluating BMB-101

- BMB-101 demonstrated a complete elimination of drop attacks in the DBA/2 mouse model - - The DBA/2 model is…

7 months ago